🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Bafna Pharmaceuticals Limited BAFNAPH NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.bafnapharma.com
Company Profile ↓
₹238.15
+181.63% 1Y
Mkt Cap₹563.38 Cr
P/E50.78
P/B5.14
52W High₹243.01
52W Low₹81.38
Book Value₹40.64
EPS (TTM)₹4.69

Company Overview

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.39.

Recent Developments

  • Mar 2026 Revenue of ₹150.62 Cr (+3.3% YoY); net profit ₹11.10 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +3.3%, earnings +167.3%.
  • 5-Year Trend Long-term compounding — revenue CAGR 9.3%, profit CAGR -0.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:9.30%
1 Year:3.26%

Compounded Profit Growth

5 Years:-0.71%
1 Year:167.30%

Stock Price Performance

1 Year:+181.63%
6 Months:+101.98%
3 Months:+78.35%
1 Month:+22.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 97% of range
₹81.38 ₹243.01
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)71.63 · Overbought
Price Performance
1M+22.33%
3M+78.35%
6M+101.98%
1Y+181.63%
Valuation vs Sector

P/E of 50.78 is above the sector median of 38.45 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 50.8.
  • Earnings shrank at -0.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
50.78
Industry PE
38.45
Forward P/E est.
25.39
PEG Ratio
-
Book Value
₹40.64
Price to Book
5.14
P/S
3.28
EV/EBITDA
33.23
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
9.30%
Profit 5Y
-0.71%
Revenue (YoY)
3.26%
Earnings (YoY)
167.30%

Profitability & Returns

ROCE
12.36%
ROE
11.54%
ROA
6.32%
Profit Margin
7.37%
Op Margin
6.56%
Gross Margin
31.96%
EPS (Latest Qtr)
₹1.16
EPS (TTM)
₹4.69

Balance Sheet & Liquidity

Debt/Equity
0.39
Quick Ratio
1.06
Current Ratio
1.57
Debt
₹37.43 Cr
Total Assets
₹175.53 Cr
Current Assets
₹89.65 Cr
Working Capital
₹32.46 Cr

Ownership

Promoter Holding
90.22%
Chg in Prom Hold
15.22%
FII / Inst Holding
0.00%
Chg in FII Hold
-9.34%

Financial Snapshot

Enterprise Value
₹563.38 Cr
Total Revenue (TTM)
₹150.62 Cr
EBITDA
₹20.70 Cr
Free Cash Flow
₹-9.53 Cr
Operating Cash Flow
₹15.37 Cr
Shares Outstanding
₹2.37 Cr
Gross Margin
31.96%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 BAFNAPH Bafna Pharmaceuticals Limited NSEPHARMA 238.15 50.78 ₹563.38 Cr 0.00% 12.36% 11.54% 9.30% -0.71%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,941.10 40.61 ₹4.66 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,248.50 74.92 ₹1.92 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,961.50 87.86 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,805.50 65.21 ₹1.27 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,410.60 21.62 ₹1.14 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,108.70 22.13 ₹1.12 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,370.50 20.36 ₹1.08 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,080.40 98.13 ₹1.05 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Jun 2018Sep 2018Jun 2019Sep 2019Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 11.95 Cr8.84 Cr6.85 Cr11.57 Cr-39.06 Cr34.62 Cr35.47 Cr38.29 Cr42.24 Cr
Cost of Revenue -----26.58 Cr22.42 Cr23.06 Cr27.27 Cr29.74 Cr
Gross Profit -----12.48 Cr12.21 Cr12.41 Cr11.02 Cr12.50 Cr
Operating Expenses 13.77 Cr8.66 Cr9.71 Cr11.95 Cr-9.58 Cr8.51 Cr9.60 Cr9.54 Cr10.62 Cr
Operating Income -2.82 Cr-57.00 L-3.88 Cr-1.10 Cr-2.90 Cr3.70 Cr2.81 Cr1.48 Cr1.89 Cr
EBITDA -1.82 Cr18.00 L-2.86 Cr-38.00 L-2.35 Cr5.66 Cr5.46 Cr4.27 Cr5.31 Cr
Interest Expense 83.00 L62.00 L13.00 L4.00 L-82.22 L90.54 L86.43 L86.24 L1.03 Cr
Pretax Income -3.56 Cr-1.22 Cr-3.71 Cr-55.00 L-1.31 Cr3.39 Cr3.12 Cr1.84 Cr2.62 Cr
Tax Provision 3.99 L-5.00 L1.58 Cr-4.00 L-0000-12.96 L
Net Income -3.52 Cr-1.28 Cr-2.13 Cr-59.00 L-1.31 Cr3.39 Cr3.12 Cr1.84 Cr2.75 Cr
Diluted EPS -1.49-0.54-0.90-2.49-0.551.431.320.781.16

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 129.00 Cr175.00 Cr185.00 Cr97.00 Cr85.00 Cr65.00 Cr46.00 Cr44.00 Cr42.00 Cr-115.35 Cr152.47 Cr145.86 Cr150.62 Cr
Cost of Revenue ----------76.59 Cr106.91 Cr103.06 Cr102.48 Cr
Gross Profit ----------38.76 Cr45.56 Cr42.80 Cr48.13 Cr
Operating Expenses 110.00 Cr153.00 Cr162.00 Cr114.00 Cr85.00 Cr71.00 Cr81.00 Cr57.00 Cr41.00 Cr-26.69 Cr39.03 Cr36.51 Cr38.26 Cr
Operating Income 13.00 Cr14.00 Cr14.00 Cr-24.00 Cr-4.00 Cr-10.00 Cr-39.00 Cr-16.00 Cr-2.00 Cr-12.07 Cr6.53 Cr6.29 Cr9.88 Cr
EBITDA 19.00 Cr22.00 Cr23.00 Cr-18.00 Cr1.00 Cr-6.00 Cr-35.00 Cr-13.00 Cr1.00 Cr-18.75 Cr14.28 Cr11.77 Cr20.70 Cr
Interest Expense 8.00 Cr12.00 Cr13.00 Cr13.00 Cr13.00 Cr11.00 Cr7.00 Cr2.00 Cr0-1.80 Cr1.94 Cr2.73 Cr3.66 Cr
Pretax Income 5.00 Cr5.00 Cr2.00 Cr6.00 Cr-15.00 Cr-20.00 Cr-15.00 Cr-17.00 Cr-24.00 Cr-11.62 Cr7.35 Cr4.15 Cr10.97 Cr
Tax Provision 3.20 Cr1.35 Cr84.00 L-12.00 L15.00 L80.00 L-2.25 Cr-1.02 Cr-0-27.83 L00-12.96 L
Net Income 2.00 Cr4.00 Cr1.00 Cr6.00 Cr-15.00 Cr-19.00 Cr-17.00 Cr-18.00 Cr-24.00 Cr-11.34 Cr7.35 Cr4.15 Cr11.10 Cr
Diluted EPS 1.002.120.753.31-7.52-10.23-7.08-7.98-104.54-4.793.111.764.69

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 219.00 Cr261.00 Cr236.00 Cr200.00 Cr193.00 Cr178.00 Cr138.00 Cr119.00 Cr71.00 Cr-129.58 Cr147.68 Cr153.08 Cr175.53 Cr
Current Assets ----------87.31 Cr93.77 Cr84.73 Cr89.65 Cr
Cash & Equivalents ----------7.81 Cr1.40 Cr3.43 Cr2.02 Cr
Inventory ----------22.22 Cr29.64 Cr28.09 Cr28.90 Cr
Receivables ----------41.15 Cr45.39 Cr40.17 Cr43.93 Cr
Total Liabilities ----------56.13 Cr66.84 Cr68.27 Cr79.38 Cr
Current Liabilities ----------46.48 Cr54.08 Cr51.85 Cr57.19 Cr
Long Term Debt ----------8.43 Cr10.75 Cr14.03 Cr17.78 Cr
Total Debt 85.00 Cr100.00 Cr108.00 Cr69.00 Cr80.00 Cr82.00 Cr47.00 Cr46.00 Cr3.00 Cr-22.92 Cr24.39 Cr28.20 Cr37.43 Cr
Total Equity 63.00 Cr68.00 Cr69.00 Cr72.00 Cr58.00 Cr43.00 Cr38.00 Cr19.00 Cr51.00 Cr-73.45 Cr80.84 Cr84.81 Cr96.15 Cr
Shares Outstanding ----------2.37 Cr2.37 Cr2.37 Cr2.37 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 29.00 Cr37.00 Cr2.00 Cr11.00 Cr1.00 Cr-1.00 Cr-7.00 Cr-2.00 Cr-34.00 Cr-4.95 Cr9.48 Cr22.14 Cr15.37 Cr
Investing Cash Flow -38.00 Cr-6.00 Cr-7.00 Cr60.00 Cr-0-5.00 Cr38.00 Cr15.00 Cr33.00 Cr--7.49 Cr-15.05 Cr-21.16 Cr-22.40 Cr
Financing Cash Flow -1.00 Cr-12.00 Cr-13.00 Cr-71.00 Cr-1.00 Cr6.00 Cr-31.00 Cr-14.00 Cr7.00 Cr-10.18 Cr-84.54 L1.06 Cr5.62 Cr
Capital Expenditure -30.00 Cr-3.00 Cr-2.00 Cr33.00 Cr-2.00 Cr047.00 Cr5.00 Cr-2.00 Cr--8.22 Cr-15.85 Cr-21.86 Cr-24.90 Cr
Free Cash Flow -1.00 Cr34.00 Cr-044.00 Cr-1.00 Cr-1.00 Cr40.00 Cr3.00 Cr-36.00 Cr--3.27 Cr-6.36 Cr27.62 L-9.53 Cr
Net Change in Cash -9.00 Cr19.00 Cr-18.00 Cr-0-0-00-06.00 Cr-7.64 Cr-6.41 Cr2.04 Cr-1.41 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----------33.6%29.9%29.3%32.0%
Operating Margin % 10.1%8.0%7.6%-24.7%-4.7%-15.4%-84.8%-36.4%-4.8%-10.5%4.3%4.3%6.6%
Net Margin % 1.6%2.3%0.5%6.2%-17.6%-29.2%-37.0%-40.9%-57.1%-9.8%4.8%2.8%7.4%
ROE % 3.2%5.9%1.4%8.3%-25.9%-44.2%-44.7%-94.7%-47.1%-15.4%9.1%4.9%11.5%
ROCE % ----------14.5%7.0%6.2%8.3%

Shareholding Pattern

Insiders
90.22%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BAFNAPH

Google News Sun, 26 Jul 2026

Bafna Pharmaceuticals Limited Revenue Breakdown – NSE:BAFNAPH - TradingView

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9vV3NyT3RSMmh6WUpZdUZMVkFHQXZUR0YxQlhhd1VsZzZqUmpRdXFvbTk2aFduaEtmUi0zN2hicS1yWGVLdGM0c1ZHR2VlMHJ5MEZsQVRCcWJHWmJ5cE1KWHJjd3duMEZfWkt2TlJEZW9VLVppeW9F?oc=5" target="_blank">Bafna P…

Google News Wed, 12 Nov 2025

The one-year returns for Bafna Pharmaceuticals' (NSE:BAFNAPH) shareholders have been strong, yet its earnings growth was even better - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxPSGlSVFdaeFY3TURwYndsYXZkMHlqZmNqWDFhOVo1emlHd2o1VEg3c09CM2tfWmZ6MDVUN3piZk93Tzc3MDFRUm03ZjdYbVlEQ3VucDU3dnhQZF9FOFVKT2JKekFrVlF6S3FNbHk3dW45dFcwQ25JTzZYWDV2bV83Q1pkYXlpX0EyVEc2Un…

Google News Fri, 26 Sep 2025

BAFNAPH Share Price Today - Bafna Pharmaceuticals Stock Analysis - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1yZEdmTGcwaTg3MkdvTG00U0dYYjZSYVhTbWlTNEJEeVRMNk8zVFh6eTNhdXNSQzFSdDFZZnZuX3FWVDNGUTBQSHhVZHUxWTJVdmdyTW54WmVHTmQ3?oc=5" target="_blank">BAFNAPH Share Price Today - Bafna Pharmaceu…

Google News ue, 09 Jun 2026

AHCL Stock Price and Chart — NSE:AHCL - TradingView

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1heGxyZ0VuSFZzUW9YYjNsNVVCM2lhSzR4NEJ5YzZncG5WN2F0b0V5UVpETGZWUDJrUmJweHhiaGFjYmhjOEpCRHZONW9HaVV3amY3bXdvWl8?oc=5" target="_blank">AHCL Stock Price and Chart — NSE:AHCL</a>&nbsp;&…

Google News Wed, 27 May 2026

Bafna Pharmaceuticals promoter confirms no share encumbrance in FY26 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPcmxWZXFGX3M5bGprQzJod1RBeEl3Ynh4RkFnc0lMQXlGa0J3WHVaMXgtYWJReWt5V1hjdW1zN3lVSlcwOVYzb1pnTmozRjdvRTIxa3dFUy0ySHlmdnUwRE1WVWJ5Vmg2bm44d2cwNGpEUkpkLWw1eTlmYzhDRTZ6eVhoS0FLV0NSLW01ZE…

Google News Mon, 20 Apr 2026

PRAVEG Stock Price and Chart — NSE:PRAVEG - TradingView

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE5OUjFjSldvdWZuOUxWNnAtMTBvQlhIRDA0bWwtQlE0eE16eGVRd2lmM0hhSUFuOVdzWFBacGFvV0kwM1E2RDl5a2ZxYUE5dXh4NzhCXzNLVGhrRXc?oc=5" target="_blank">PRAVEG Stock Price and Chart — NSE:PRAVEG</a…

BAFNAPH — Frequently Asked Questions

What is the current share price of Bafna Pharmaceuticals Limited (BAFNAPH)?

As of 2026-07-27 05:56 IST, Bafna Pharmaceuticals Limited (BAFNAPH) trades at ₹238.15 on NSE. Its 52-week range is ₹81.38 to ₹243.01.

What is the market capitalisation of BAFNAPH?

Bafna Pharmaceuticals Limited (BAFNAPH) has a market capitalisation of ₹563.38 Cr on NSE.

What is the P/E ratio of BAFNAPH?

BAFNAPH trades at a trailing price-to-earnings (P/E) ratio of 50.78. The industry average P/E is 38.45. Its price-to-book (P/B) ratio is 5.14.

What is the return on equity (ROE) of BAFNAPH?

BAFNAPH has a return on equity (ROE) of 11.54%. Its return on capital employed (ROCE) is 12.36%.

Is BAFNAPH a good stock to buy?

This page provides a data-driven analysis of Bafna Pharmaceuticals Limited (BAFNAPH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space